| 000 | 01495 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250516155604.0 | ||
| 264 | 0 | _c20151016 | |
| 008 | 201510s 0 0 cze d | ||
| 022 | _a0042-773X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPenka, M | |
| 245 | 0 | 0 |
_a[The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012]. _h[electronic resource] |
| 260 |
_bVnitrni lekarstvi _cJun 2013 |
||
| 300 |
_a516-31 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCzech Republic |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyeloproliferative Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aQuinazolines _xtherapeutic use |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 |
_aThrombocythemia, Essential _xdrug therapy |
| 650 | 0 | 4 |
_aThrombosis _xepidemiology |
| 700 | 1 | _aSchwarz, J | |
| 700 | 1 | _aOvesná, P | |
| 700 | 1 | _aCervinek, L | |
| 700 | 1 | _aDulíček, P | |
| 700 | 1 | _aPospíšilová, D | |
| 700 | 1 | _aKissová, J | |
| 700 | 1 | _aPavlík, T | |
| 773 | 0 |
_tVnitrni lekarstvi _gvol. 59 _gno. 6 _gp. 516-31 |
|
| 999 |
_c22874327 _d22874327 |
||